Skip to main content
Department of Pharmaceutics

Research

Our research plan for the next 5 years (2019-2023):

Main research activities

Several active research groups in the department are engaged with different aspects of pharmaceutics. The research is directed towards high quality innovative topics aiming to publish applied articles.

The research plan in the period from 2019 till 2023 is still focusing on three distinct areas:

  1. Nanotechnology as a promising area of pharmaceutical science is a target for formulation of many drugs.
  2. Preformulation studies to improve the characteristics of drugs and/or dosage forms and development of more acceptable dosage forms.
  3. Targeted drug delivery systems

 

 

# Title Research Year
51 Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical Applications 2020
52 Pleurotus sajor-caju-Mediated Synthesis of Silver and Gold Nanoparticles Active against Colon Cancer Cell Lines: A New Era of Herbonanoceutics 2020
53 Epigallocatechin-3-Gallate-Loaded Gold
Nanoparticles: Preparation and Evaluation of
Anticancer Efficacy in Ehrlich Tumor-Bearing Mice
2020
54 Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids 2020
55 Modulation of rifampicin-induced hepatotoxicity using poly(lactic-co-glycolic acid) nanoparticles: a study on rat and cell culture models 2020
56 Polymeric micelles for the ocular delivery of triamcinolone acetonide: preparation and in vivo evaluation in a rabbit ocular inflammatory model 2020
57 Epigallocatechin-3-Gallate-Loaded Gold
Nanoparticles: Preparation and Evaluation of
Anticancer Efficacy in Ehrlich Tumor-Bearing Mice
2020
58 Development of Bi-Polymer Lipid Hybrid Nanocarrier (BLN) to Improve the Entrapment and Stability of Insulin for Efficient Oral Delivery 2019
59 A Multifunctional Lipid-based Nanodevice for the Highly-specific Co-delivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells 2019
60 A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation 2019